192 related articles for article (PubMed ID: 18498705)
1. Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype.
Conrado DJ; Verli H; Neves G; Fraga CA; Barreiro EJ; Rates SM; Dalla Costa T
J Pharm Pharmacol; 2008 Jun; 60(6):699-707. PubMed ID: 18498705
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats.
Tasso L; Neves G; Menegatti R; Fraga CA; Barreiro E; Eifler-Lima V; Rates SM; Costa TD
Eur J Pharm Sci; 2005 Oct; 26(2):194-202. PubMed ID: 16076552
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pharmacokinetics, brain levels and protein binding of centpropazine in rats.
Bhattaram VA; Paliwal JK; Gupta RC
Biopharm Drug Dispos; 2004 Mar; 25(2):69-75. PubMed ID: 14872554
[TBL] [Abstract][Full Text] [Related]
4. Leishmanicidal candidate LASSBio-1736, a cysteine protease inhibitor with favorable pharmacokinetics: low clearance and good distribution.
Moraes BS; Azeredo FJ; Izoton JC; Amaral M; Barreiro EJ; Freddo RJ; Dalla Costa T; Lima LM; Haas SE
Xenobiotica; 2018 Dec; 48(12):1258-1267. PubMed ID: 29160126
[TBL] [Abstract][Full Text] [Related]
5. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
[TBL] [Abstract][Full Text] [Related]
6. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus.
Leal N; Calvo R; Agrad FZ; Lukas JC; de la Fuente L; Suarez E
J Pharm Pharmacol; 2005 Mar; 57(3):317-25. PubMed ID: 15807987
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma.
Xu W; Sun J; Zhang TT; Ma B; Cui SM; Chen DW; He ZG
Acta Pharmacol Sin; 2006 Dec; 27(12):1642-6. PubMed ID: 17112421
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581.
Neves G; Kliemann M; Betti AH; Conrado DJ; Tasso L; Fraga CA; Barreiro EJ; Teresa Dalla Costa ; Rates SM
Pharmacol Biochem Behav; 2008 Mar; 89(1):23-30. PubMed ID: 18082872
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats.
Nicolazzo JA; Nguyen TT; Katneni K; Steuten JA; Smith G; Jarrott B; Callaway JK; Charman SA
J Pharm Pharmacol; 2008 Feb; 60(2):171-8. PubMed ID: 18237464
[TBL] [Abstract][Full Text] [Related]
10. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
[TBL] [Abstract][Full Text] [Related]
11. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417.
Scott-Stevens P; Atack JR; Sohal B; Worboys P
Biopharm Drug Dispos; 2005 Jan; 26(1):13-20. PubMed ID: 15578749
[TBL] [Abstract][Full Text] [Related]
12. Disposition of abouthiouzine: a novel antihyperthyroid drug.
Alkharfy KM; Khan RM; Al-Hadiya BM; Abou-Auda HS; Abou-Shaaban RR
Biopharm Drug Dispos; 2007 Apr; 28(3):105-11. PubMed ID: 17230598
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats.
Kapetanovic IM; Muzzio M; McCormick DL; Thompson TN; Johnson WD; Horn TL; Mohammed A; Rao CV; Kopelovich L
Cancer Chemother Pharmacol; 2012 May; 69(5):1301-6. PubMed ID: 22302406
[TBL] [Abstract][Full Text] [Related]
14. Preliminary pharmacokinetics of a new pyridopyrimidine derivative.
Pérez MJ; Roch MJ; Ochoa MC
Arzneimittelforschung; 1991 Jun; 41(6):640-4. PubMed ID: 1930354
[TBL] [Abstract][Full Text] [Related]
15. Dose-dependent pharmacokinetics of a new Na+/H+ exchanger inhibitor KR-33028 in rats.
Kim YH; Yoo SD; Kim YS; Lee KH; Lee HS
Biopharm Drug Dispos; 2007 Nov; 28(8):423-9. PubMed ID: 17828714
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical pharmacokinetics evaluation of an anticonvulsant candidate benzaldehyde semicarbazone free and included in beta-cyclodextrin.
Kaiser M; Azeredo FJ; Uchôa Fde T; Beraldo Hde O; Dalla Costa T
Eur J Pharm Sci; 2010 Mar; 39(5):355-62. PubMed ID: 20093185
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration.
Goudah A; Abo El-Sooud K; Shim JH; Shin HC; Abd El-Aty AM
J Vet Pharmacol Ther; 2008 Oct; 31(5):399-405. PubMed ID: 19000258
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of trazodone after different routes of administration.
Rurak A; Melzacka M; Danek L
Pol J Pharmacol Pharm; 1981 Oct; 33(3):341-8. PubMed ID: 7322946
[TBL] [Abstract][Full Text] [Related]
19. Analytical determination and pharmacokinetics of robenacoxib in the dog.
Jung M; Lees P; Seewald W; King JN
J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of difloxacin in pigs and broilers following intravenous, intramuscular, and oral single-dose applications.
Ding HZ; Yang GX; Huang XH; Chen ZL; Zeng ZL
J Vet Pharmacol Ther; 2008 Jun; 31(3):200-4. PubMed ID: 18471140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
